Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 3755 Côte Ste-Catherine Road, Suite H-413, Montréal, Québec, H3T 1E2, Canada.
BMJ. 2019 Aug 1;366:l4410. doi: 10.1136/bmj.l4410.
To determine if genetically increased serum calcium levels are associated with improved bone mineral density and a reduction in osteoporotic fractures.
Mendelian randomisation study.
Cohorts used included: the UK Biobank cohort, providing genotypic and estimated bone mineral density data; 25 cohorts from UK, USA, Europe, and China, providing genotypic and fracture data; and 17 cohorts from Europe, providing genotypic and serum calcium data (summary level statistics).
A genome-wide association meta-analysis of serum calcium levels in up to 61 079 individuals was used to identify genetic determinants of serum calcium levels. The UK Biobank study was used to assess the association of genetic predisposition to increased serum calcium with estimated bone mineral density derived from heel ultrasound in 426 824 individuals who had, on average, calcium levels in the normal range. A fracture genome-wide association meta-analysis comprising 24 cohorts and the UK Biobank including a total of 76 549 cases and 470 164 controls, who, on average, also had calcium levels in the normal range was then performed.
A standard deviation increase in genetically derived serum calcium (0.13 mmol/L or 0.51 mg/dL) was not associated with increased estimated bone mineral density (0.003 g/cm, 95% confidence interval -0.059 to 0.066; P=0.92) or a reduced risk of fractures (odds ratio 1.01, 95% confidence interval 0.89 to 1.15; P=0.85) in inverse-variance weighted mendelian randomisation analyses. Sensitivity analyses did not provide evidence of pleiotropic effects.
Genetic predisposition to increased serum calcium levels in individuals with normal calcium levels is not associated with an increase in estimated bone mineral density and does not provide clinically relevant protection against fracture. Whether such predisposition mimics the effect of short term calcium supplementation is not known. Given that the same genetically derived increase in serum calcium is associated with an increased risk of coronary artery disease, widespread calcium supplementation in the general population could provide more risk than benefit.
确定血清钙水平升高是否与骨密度增加和骨质疏松性骨折减少有关。
孟德尔随机研究。
使用的队列包括:英国生物库队列,提供基因型和估计骨密度数据;来自英国、美国、欧洲和中国的 25 个队列,提供基因型和骨折数据;以及来自欧洲的 17 个队列,提供基因型和血清钙数据(汇总水平统计数据)。
对多达 61079 人的血清钙水平进行全基因组关联荟萃分析,以确定血清钙水平的遗传决定因素。使用英国生物库研究评估遗传易感性增加血清钙与平均处于正常钙范围内的 426824 名个体的足跟超声估计骨密度的相关性。然后对包括 24 个队列和英国生物库的骨折全基因组关联荟萃分析进行了研究,该研究共包括 76549 例病例和 470164 例对照,这些人平均也处于正常钙范围内。
遗传衍生的血清钙增加 0.13mmol/L(0.51mg/dL)与估计的骨密度增加无关(0.003g/cm,95%置信区间-0.059 至 0.066;P=0.92)或骨折风险降低无关(比值比 1.01,95%置信区间 0.89 至 1.15;P=0.85),这是在反向方差加权孟德尔随机分析中得出的结果。敏感性分析并未提供存在多效性影响的证据。
在钙水平正常的个体中,遗传易感性增加血清钙水平与估计骨密度增加无关,并且不能提供对骨折的临床相关保护。这种易感性是否模拟短期钙补充的效果尚不清楚。鉴于相同的遗传衍生血清钙增加与冠心病风险增加有关,在普通人群中广泛补充钙可能会带来更多的风险而不是益处。